Tipco Engineering India Ltd. IPO

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’) read with Para A of Part A of Schedule III thereto, Tipco Engineering India has informed that the Company has, on September 16, 2026, incorporated a subsidiary company in the name and style of ‘TIPCO DEFENCE TECHNOLOGIES & ROBOTICS’ (‘TDTRPL’), vide Certificate of Incorporation bearing CIN: U28299HR2026PTC150593 issued by the Registrar of Companies, Haryana. In terms of the approval accorded by the Board of Directors of the Company at its meeting held on August 31,2026 the Company has subscribed to 5,100 equity shares of ₹10 each of TDTRPL, aggregating to ₹51,000, constituting 51% of the subscribed and paid-up equity share capital of TDTRPL. Accordingly, TDTRPL has become a subsidiary of the Company with effect from September 16, 2026. Further, the detailed disclosure as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 is enclosed as Annexure-A. A copy of the same will also be uploaded on the Company’s website. https://tipcoengineering.com/. 

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 30 read with Schedule III Part A (A) and in compliance of Regulation 47(1)(b) of the SEBI (LODR) Regulations, 2015, Tipco Engineering India has informed that the Notice of the 1st Extra-Ordinary General Meeting (‘EGM’) which is scheduled to be held on Thursday, 17th September 2026 at 02:30 pm through Video Conferencing/Other Audio Visual means, has been published in the Newspapers. The company has enclosed the newspaper clipping of notice published on August 27, 2026 in Financial Express- English and Jansatta – Hindi.

Tipco Engineering India informed about that outcome of meeting of the Board of Directors of Tipco Engineering India Limited (“the Company”) in terms of the provisions of Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The above information is a part of company’s filings submitted to BSE.

Himalaya Nutravedics India

• Himalaya Nutravedics India is coming out with an initial public offering (IPO) of 24,99,600 shares in a price band of Rs 100-106 per equity share.
• The issue will open for subscription on September 22, 2026 and will close on September 24, 2026.
• The shares will be listed on SME Platform of BSE.
• The face value of the share is Rs 10 and is priced 10.00 times of its face value on the lower side and 10.60 times on the higher side.
• Book running lead manager to the issue is Nirbhay Capital Services.
• Compliance officer for the issue is Pooja Biyani.

Profile of the company

Himalaya Nutravedics India is engaged in the manufacturing, marketing and distribution of Ayurvedic and Nutraceutical formulations in India and also undertakes third-party contract manufacturing for other Ayurvedic and Nutraceutical companies. The company manufactures a diversified portfolio comprising classical (Shastric) Ayurvedic formulations, which are based on compositions and processes described in traditional Ayurvedic texts such as Charaka Samhita, Sushruta Samhita, Ashtanga Hridaya, Bhaishajya Ratnavali and other recognized Ayurvedic compendia, proprietary Ayurvedic formulations and Nutraceutical products across multiple dosage forms, including soft gelatin capsules, hard gelatin capsules, tablets, Liquid orals, Medicated oils.

The company operates through a hybrid business model that balances its own formulations with third-party manufacturing operations. Under its own-brand business segment, it formulates, manufactures and markets products across three categories: classical Ayurvedic formulations, proprietary Ayurvedic formulations and nutraceutical supplements. 

Currently, the company has established a pan-India presence across multiple states, supported by a stockiest driven distribution network and an on-ground sales and marketing team comprising approximately 56 personnel, including regional managers and medical representatives. Currently, the company follows a doctor-centric, offline marketing model focused on scientific detailing, continuing medical education programs, medical camps and relationship-based engagement, rather than mass-media advertising.

Proceed is being used for:

• Funding working capital requirements 
• Investing in branding, digital marketing and sales expansion
• General corporate purposes

Industry overview

The Ayurvedic Formulations and Nutraceuticals Industry is a specialised segment within India’s pharmaceutical and wellness ecosystem, covering the manufacture of Ayurvedic, herbal, and dietary supplements under NIC divisions for pharmaceuticals, AYUSH products, and food preparations. It focuses on developing and commercialising condition-oriented formulations combining botanicals, minerals, vitamins, amino acids, fatty acids, and probiotics, delivered in tablets, capsules, softgels, syrups, powders, oils, and medicated ghee.

India’s AYUSH sector - encompassing Ayurveda, Yoga & Naturopathy, Unani, Siddha, and Homeopathy- constitutes a significant component of the consumer healthcare ecosystem, with combined manufacturing and service activity valued at over $50 billion in 2024 (manufacturing $24 billion, services $26 billion). The Union Budget for FY26 allocated Rs 3,992.9 crore to the Ministry of AYUSH, a 14.2% increase from FY25, while AYUSH exports reached Rs 5,907 crore in FY25, up 5.9% YoY. The AYUSH market is projected to expand from $43.3 billion in 2024 to $200 billion by 2030.

The nutraceuticals and Ayurveda industries in India operate within a structured and evolving policy environment that encompasses food safety regulation, traditional medicine governance, manufacturing quality standards, institutional healthcare integration, and export facilitation. Regulatory oversight for these industries is exercised through a dual framework, with the Food Safety and Standards Authority of India (FSSAI) governing health supplements and novel foods, and the Ministry of AYUSH regulating traditional formulations, supported by Schedule M manufacturing norms and WHO-GMP standards. Government policy orientation in this sector is directed toward strengthening domestic manufacturing capacity, improving regulatory standardization, enabling participation of MSMEs, integrating traditional systems into public healthcare delivery, and enhancing the global competitiveness of Indian wellness products.

Pros and strengths

Integrated multi-dosage manufacturing capability: The company operates an integrated manufacturing facility with the capability to manufacture a wide range of dosage forms, including medicated oils, soft gelatin capsules, hard gelatin capsules, tablets and liquid orals. This multi-dosage capability allows the company to address diverse therapeutic requirements and customer preferences across both Ayurvedic and nutraceutical segments. The company’s manufacturing breadth enables it to develop, scale and commercialise products across multiple formats without reliance on external manufacturers, supporting faster product launches and efficient utilisation of manufacturing infrastructure.

Doctor acceptance supported by product performance rather than mass advertising: The company’s Ayurvedic and Nutraceutical formulations have achieved repeat prescriptions and re-ordering by healthcare practitioners despite limited reliance on mass media or consumer-facing advertising. The company’s marketing approach is focused on scientific detailing (i.e., structured, evidence-based engagement with healthcare practitioners through clinical data and product literature), continuing medical education (CME) programmes, medical camps and practitioner engagement. This approach indicates practitioner acceptance based on product performance, formulation relevance and consistency of supply. It also allows the company to control marketing costs and focus resources on targeted engagement, rather than large-scale advertising expenditure.

Broad therapeutic coverage across ayurvedic and nutraceutical segments: Ayurvedic and nutraceutical products support preventive care, chronic disease co-management, and post-treatment recovery, complementing allopathic therapies in areas such as osteoporosis, arthritis, infertility, anemia, renal calculi, lifestyle-related metabolic disorders, and pediatric development. The company’s product portfolio spans multiple therapeutic and wellness categories, including gut health, cardiac and metabolic wellness, diabetes management, pain management, immunity, infertility and general wellness. The portfolio includes both classical Ayurvedic formulations, proprietary Ayurvedic formulations and Nutraceutical blends. This breadth allows the company to address varied prescribing needs of healthcare practitioners and enables cross selling across therapeutic areas.

Risks and concerns

High revenue concentration in ayurvedic products: The company derives a significant portion of its revenue from the sale of products in the Ayurvedic products which constituted 94.57%, 92.09% and 79.27% of its revenue from operations for the Fiscals 2026, 2025 and 2024, respectively. Any reduction in demand or a temporary or permanent discontinuation of manufacturing of products in these therapeutic areas could have an adverse effect on its business, results of operations, financial condition and cash flows. Its revenue from sales of these products may decline as a result of increased market acceptance for its competitors’ products instead of its, breakthroughs in the development of more effective or popular alternative products, regulatory action, pricing pressures or fluctuations in the demand for or supply of its products.

Reliance on top 10 customers for revenue: The company is dependent on and derive a substantial portion of its revenue from certain key customers. Revenue generated from its top 10 customers accounted for 81.24%, 86.97%, and 84.19%, of its revenue from operations during the Fiscals 2026, 2025 and 2024, respectively. Loss of relationship with any of these customers or delays or reductions in their orders may have an adverse effect on its business, results of operations, financial condition and cash flows.

Dependence on growth and performance of ayurvedic industry: The company is primarily engaged in the manufacturing of Ayurvedic products, and its business and revenues are closely linked to the overall performance and growth of the Ayurvedic industry. Any slowdown, reduced consumer acceptance or adverse developments affecting the Ayurvedic industry could negatively impact demand for its products and, consequently, its business, results of operations, financial condition and cash flows. The industry is influenced by several factors, including evolving consumer preferences, competition from other systems of medicine, changes in healthcare trends, regulatory developments and the availability and pricing of herbal raw materials. Any shift in consumer preferences away from Ayurvedic products, increased adoption of alternative therapies, or changes in regulatory standards applicable to Ayurvedic products may adversely affect demand for its products.

Outlook

Himalaya Nutravedics India is engaged in the formulation and manufacture of Ayurvedic and nutraceutical products. The company’s product portfolio is focused on condition-oriented formulations across fertility, maternal health, bone and joint care, metabolic disorders, urology, paediatrics, neurocognitive health and general wellness. The company’s products are positioned for prescription-adjacent usage and are primarily marketed to medical practitioners across specialties such as gynaecology, orthopaedics, nephrology, paediatrics, diabetology and general medicine through a doctor-led and pharmacy-based distribution network. On the concern side, it does not enter into long-term agreements with certain of its key suppliers for procurement of raw materials, including herbal and nutraceutical ingredients, or with its customers and distributors. As a result, its arrangements with such parties are generally on a purchase order basis. The absence of long-term contracts exposes it to risks such as volatility in raw material prices, disruption in supply, and loss of customers without prior notice. Any such disruption may adversely affect its production, sales and overall business operations.

The company is coming out with a maiden IPO of 24,99,600 equity shares of face value of Rs 10 each. The issue has been offered in a price band of Rs 100-106 per equity share. The aggregate size of the offer is around Rs 25.00 crore to Rs 26.50 crore based on lower and upper price band respectively. On performance front, Revenue from operations increased by 105.12% to Rs 4,306.75 lakh in FY 2025-26, from Rs 2,099.65 lakh in FY 2024-25. Restated Profit After Tax (PAT) for FY 2025-26 increased to Rs 738.97 lakh, as compared to Rs 223.18 lakh in FY 2024-25.

Meanwhile, the company aims to strengthen and scale its business of classical Ayurvedic, proprietary Ayurvedic and nutraceutical business across India by expanding its geographic footprint and deepening market penetration. As of March 31, 2026, the company’s products are marketed across 17 states, supported by an on-ground sales and marketing organisation. The company proposes to continue expanding its field force to enhance reach and engagement with healthcare practitioners. The distribution model will be supported through the appointment and periodic rotation of stockists in strategically identified territories to improve market coverage and supply efficiency. The company follows a doctor-centric engagement approach, involving scientific detailing, continuing medical education programs, medical camps and BFD camps. This strategy is intended to drive prescription-based demand and build sustainable presence over time.